Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines

BACKGROUND: Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity. Given that drug cytotoxicity represents a major problem during treatment, i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kulkarni, Hemant, Göring, Harald H H, Diego, Vincent, Cole, Shelley, Walder, Ken R, Collier, Greg R, Blangero, John, Carless, Melanie A
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3483163/
https://ncbi.nlm.nih.gov/pubmed/22917222
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1755-8794-5-37
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados